Helicobacter pylori eradication in clinical practice: Retreatment rates and costs of competing regimens

Annals of Pharmacotherapy

Volumn 34, Issue 6, 2000, Pages 721-728

  Fairman, Kathleen A ^a   Motheral, Brenda R ^a,b  

^a Express Scripts   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Bismuth; Helicobacter pylori; Pharmacoeconomics; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETREATMENT;

EID: 0034122054     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19271     Document Type: Article

References (29)

1. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272:65-9.
2. Howden CW, Hunt RH, for and on behalf of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93:2330-8.
3. The choice of antibacterial drugs. Med Lett Drug Ther 1998;40:33-42.
4. Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med 1998;158:842-51.
5. Fennerty MB. What are the treatment goals for Helicobacter pylori infection? Gastroenterology 1997;113(suppl 6):S120-5.
6. Cutler AF, Vakil N. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease. Am J Managed Care 1997;3:1528-34.
7. Hunt RH. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori. Am J Gastroenterol 1997;92(suppl 4):36S-43S.
8. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997;43:223-43.
9. deBoer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients: a personal viewpoint. J Clin Gastroenterol 1996;22:313-6.
10. deBoer WA, Tytgat GNJ. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroentero; 1995;30:401-7.
11. Graham DY, deBoer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
12. Lerang F, Moum B, Ragnhildstveit E, Sandvei PK, Tolas P, Whist JE, et al. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance. Am J Gastroenterol 1998; 93:212-6.
13. Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY. How do clinicians in the US manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol 1998;93:553-61.
14. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997;113(suppl 6):S131-48.
15. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996;91:246-57.
16. Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993;86:743-50.
17. Goddard AF, Spiller RC. Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 1996;10:1009-13.
18. Lerang F, Moum B, Ragnhildstveit E, Haug JB, Hauge T, Tolas P, et al. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized one-year follow-up study. Am J Gastroenterol 1997;92:653-8.
19. Reilly TG, Ayres RCS, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on quality of life in peptic ulcer. Aliment Pharmacol Ther 1995;9:483-90.
20. Saberi-Firoozi M, Massarat S, Zare S, Fattahi M, Javan A, Etaati H, et al. Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a one-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol 1995;90:1419-23.
21. Fennerty MB, Lieherman DA, Vakil N, Margaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999;159:1562-6.
22. Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87-97.
23. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens tor the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996;91:239-45.
24. SPSS version 7.5. SPSS, Inc., Chicago, IL.
25. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996;275:622-9.
26. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997;113(suppl 6):S4-8.
27. Roos L, Sharp SM, Cohen MM. Comparing clinical information with claims data: some similarities and differences. J Clin Epidemiol 1991; 44:881-8.
28. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med 1985;20:29-37.
29. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.